Integrin β5 and β7 expression in lenalidomide-resistant multiple myeloma cells

Int J Hematol. 2022 Apr;115(4):605-608. doi: 10.1007/s12185-022-03297-w. Epub 2022 Feb 23.

Authors

Yutaka Hattori^{1

2}, Takumi Futo³, Ryo Uozaki³, Daiju Ichikawa³, Takashi Yamaguchi³, Tomofumi Yamamoto³, Maiko Matsushita³, Maki Hirao⁴

Affiliations

¹ Division of Clinical Physiology and Therapeutics, Keio University Faculty of Pharmacy, Tokyo, Japan. hattori-yt@pha.keio.ac.jp.
² Division of Hematology, Department of Medicine, Saiseikai Central Hospital, Tokyo, Japan. hattori-yt@pha.keio.ac.jp.
³ Division of Clinical Physiology and Therapeutics, Keio University Faculty of Pharmacy, Tokyo, Japan.
⁴ Division of Hematology, Department of Medicine, Saiseikai Central Hospital, Tokyo, Japan.

PMID: 35194739
DOI: 10.1007/s12185-022-03297-w

No abstract available

Publication types

Letter
Comment

MeSH terms

Cell Line, Tumor
Humans
Integrin beta Chains
Lenalidomide
Multiple Myeloma* / drug therapy
Multiple Myeloma* / genetics
Multiple Myeloma* / metabolism

Substances

Integrin beta Chains
integrin beta5
Lenalidomide

Grants and funding